Quarterly report pursuant to Section 13 or 15(d)

Consolidated Condensed Statements of Operations

v2.4.0.6
Consolidated Condensed Statements of Operations (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Revenue:        
PCT products, services, other $ 297,867 $ 217,734 $ 687,023 $ 589,063
Grant revenue 93,749 62,688 335,162 62,688
Total revenue 391,616 280,422 1,022,185 651,751
Costs and expenses:        
Cost of PCT products and services 108,689 93,610 296,086 250,835
Research and development 247,717 248,188 775,635 730,962
Selling and marketing 164,313 193,975 570,578 740,358
General and administrative 557,417 490,460 1,713,778 1,351,303
Total operating costs and expenses 1,078,136 1,026,233 3,356,077 3,073,458
Operating loss (686,520) (745,811) (2,333,892) (2,421,707)
Other (expense) income:        
Interest (expense) income (10,540) (39,358) (71,067) (39,029)
Change in fair value of warrant derivative liability (98,978) 223,446 36,322 307,467
Total other (loss) income (109,518) 184,088 (34,745) 268,438
Net loss (796,038) (561,723) (2,368,637) (2,153,269)
Accrued and deemed dividends on convertible preferred stock (129,789) (392,123) (895,734) (939,574)
Net loss applicable to common shareholders $ (925,827) $ (953,846) $ (3,264,371) $ (3,092,843)
Net loss per share attributable to common stockholders - basic and diluted $ (0.09) $ (0.15) $ (0.34) $ (0.50)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation 10,872,877 6,253,349 9,598,066 6,228,585